| Literature DB >> 24130632 |
Adriana Polańska1, Aleksandra Dańczak-Pazdrowska, Wojciech Silny, Dorota Jenerowicz, Karolina Olek-Hrab, Agnieszka Osmola-Mańkowska.
Abstract
INTRODUCTION: Atopic dermatitis (AD) is a chronic and relapsing skin disorder, which is characterized by abnormal skin barrier function within the entire skin surface. Several noninvasive bioengineering methods have been commonly used to quantify disease severity. High-frequency ultrasonography (HF-USG) is an important contribution to this field. AIM: To evaluate noninvolved skin during the external treatment in relation to involved regions in patients with AD skin using noninvasive methods.Entities:
Keywords: atopic dermatitis; capacitance; high frequency ultrasonography; seemingly healthy skin; skin ultrasonography; transepidermal water loss
Year: 2013 PMID: 24130632 PMCID: PMC3796717 DOI: 10.5114/wiitm.2011.33633
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Characteristics of the study group in relation to the type of therapy
| Regimen | Number of patients | Main objectives | Duration [weeks] | Mean age [years] | Women [%] | Men [%] |
|---|---|---|---|---|---|---|
| tGS | 20 | Group 5-7 of tGS (twice/day on affected regions), emollients, second generation antihistamines (cetirizine 20 mg) | 3 | 22.5 | 30 | 70 |
| tCI | 25 | Pimecrolimus (twice/day on affected regions), emollients, second generation antihistamines (cetirizine 20 mg) | 3 | 25.0 | 60 | 40 |
| UVA 1 | 10 | Cycle of 20 irradiations with weekend break – dose range 30-120 J/cm2, emollients, second generation antihistamines (cetirizine 20 mg) | 4 | 33.0 | 50 | 50 |
| Total | 55 | – | – | 25.9 | 47 | 53 |
tGS – topical steroids, tCI – topical calcineurin inhibitors, UVA1 – narrow-band UVA phototherapy
The results of four selected parameters of skin function (TEWL, capacitance, erythema, skin echogenicity, SLEB) measured in AD patients and in the control group
| Skin parameter | Atopic dermatitis before therapy | Atopic dermatitis after therapy | Control group | ||
|---|---|---|---|---|---|
| Involved skin | Uninvolved skin | Involved skin | Uninvolved skin | ||
| TEWL [g/m2/h] | 33.5 ±12.4 | 17.8 ±9.3 | 21.3 ±11.8 | 13.3 ±5.3 | 13.3 ±4.7 |
| Capacitance (AU) | 19.9 ±7.9 | 28.5 ±12.5 | 26.7 ±13.5 | 29.6 ±11.3 | 44.6 ±11.9 |
| Erythema | 16.7 ±3.4 | 11.3 ±2.7 | 13.8 ±3.4 | 11.6 ±2.6 | 11.0 ±1.9 |
| Skin echogenicity [%] | 7.8 ±0.4 | 8.3 ±0.5 | 8.1 ±0.4 | 8.4 ±0.4 | 8.8 ±0.1 |
| SLEB [mm] | 0.23 ±0.1 | 0.14 ±0.1 | 0.16 ±0.1 | 0.0 | 0.0 |
TEWL – transepidermal water loss, AU – arbitrary units, SLEB – subepidermal low-echogenic band